Evidence map›Paper›PMID 24494068›Full record

ArticleIranian journal of basic medical sciences2013

Synthesis and in vitro cytotoxic activity of novel chalcone-like agents.

Bahram Letafat, Raheleh Shakeri, Saeed Emami, Saeedeh Noushini, Negar Mohammadhosseini, Nayyereh Shirkavand, Sussan Kabudanian Ardestani, Maliheh Safavi, Marjaneh Samadizadeh, Aida Letafat and 2 more

Abstract read
In one paragraph

Article in Iranian journal of basic medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Synergistic activity between conventional antifungals and chalcone-derived compound against dermatophyte fungi and Candida spp.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Article
  3. Review
  4. Chromanone-A Prerogative Therapeutic Scaffold: An Overview.Arabian journal for science and engineering · 2022
    Review
  5. Article
  6. New chroman-4-one/thiochroman-4-one derivatives as potential anticancer agents.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bahram LetafatDepartment of Chemistry, Central Tehran-Branch, Islamic Azad University, Tehran, Iran.
Raheleh ShakeriInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Saeed EmamiDepartment of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Saeedeh NoushiniDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Negar MohammadhosseiniDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Nayyereh ShirkavandDepartment of Chemistry, Central Tehran-Branch, Islamic Azad University, Tehran, Iran.
Sussan Kabudanian ArdestaniInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Maliheh SafaviInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran ; Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Marjaneh SamadizadehDepartment of Chemistry, Central Tehran-Branch, Islamic Azad University, Tehran, Iran.
Aida LetafatDepartment of Chemistry, Tabriz Branch, Islamic Azad University, Tabriz, Iran.
Abbas Sha EeDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alireza ForoumadiDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE(S): Chalcones and their rigid analogues represent an important class of small molecules having anticancer activities. Therefore, in this study the synthesis and cytotoxic activity of new 3-benzylidenchroman-4-ones were described as rigid chalcone analogues. MATERIALS AND

methodsThe reaction of resorcinol with 3-chloropropionic acid in the presence of CF3SO3H was afforded corresponding propiophenone. It was cyclized using 2M NaOH to give 7-hydroxy-4-chromanone. O-Alkylation of 7-hydroxy-4-chromanone with alkyl iodide in the presence of K2CO3 gave 7-alkoxychroman-4-one. Finally, condensation of chroman-4-one derivatives with different aldehydes afforded target compounds in good yields. The newly synthesized compounds were tested in vitro against different human cancer cell lines including K562 (human erythroleukemia), MDA-MB-231 (human breast cancer), and SK-N-MC (human neuroblastoma) cells. The cell viability was evaluated using MTT colorimetric assay.

resultsMost of the compounds showed good inhibitory activity against cancer cells. Among them, compound 4a containing 7-hydroxy group on chromanone ring and 3-bromo-4-hydroxy-5-methoxy substitution pattern on benzylidene moiety was the most potent compound with IC50 values ≤ 3.86 µg/ml. It was 6-17 times more potent than etoposide against tested cell lines.

conclusionWe described synthesis and cytotoxic activity of poly-functionalized 3-benzylidenechroman-4-ones as new chalcone-like agents. These compounds can be considered as conformationally constrained congeners of chalcones to tolerate the poly-functionalization on the core structures for further optimization.

Indexed as

4-ChromanoneChalconesCytotoxic activitySynthesis

Identifiers

PMID24494068
PMCPMC3909627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.